Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689618 | 0.85 | HTT (0.36) | HTTEPHX2 | |
| SCHEMBL2155910 | 0.81 | HTT (0.38) | HTTEPHX2 | |
| SCHEMBL2154988 | 0.80 | HTT (0.33) | HTTEPHX2 | |
| SCHEMBL1443822 | 0.80 | HTT (0.37) | HTTEPHX2 | |
| SCHEMBL9009145 | 0.79 | HTT (0.32) | HTTEPHX2 | |
| SCHEMBL689250 | 0.78 | HTT (0.34) | HTTEPHX2 | |
| SCHEMBL17032653 | 0.77 | HTT (0.33) | HTT | |
| SCHEMBL4050 | 0.75 | POLB (0.44) | — | |
| SCHEMBL2986780 | 0.75 | CHRM1 (0.35) | HTT | |
| SCHEMBL2987567 | 0.74 | HTT (0.35) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133908-B2 | Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine | GLAXO GROUP LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110086839-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| EP-2297139-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100144755-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | HTT 244/4885EPHX2 1713/4885PGK1 4819/4885 |
| US-20100144755-A1 | Novel Compounds | MAPKAPK2, CDC42BPB, MAPK8 | HTT 4806/4885EPHX2 4214/4885PGK1 1213/4885 |
| US-20120046291-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | HTT 3843/4885EPHX2 1746/4885PGK1 2218/4885 |
| US-20110086839-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | HTT 1267/4885EPHX2 1041/4885PGK1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.